s-SHIP Promoter Expression Identifies Mouse Mammary Cancer Stem Cells.


Journal

Stem cell reports
ISSN: 2213-6711
Titre abrégé: Stem Cell Reports
Pays: United States
ID NLM: 101611300

Informations de publication

Date de publication:
09 07 2019
Historique:
received: 10 07 2018
revised: 13 05 2019
accepted: 14 05 2019
pubmed: 18 6 2019
medline: 11 6 2020
entrez: 18 6 2019
Statut: ppublish

Résumé

During normal mammary gland development, s-SHIP promoter expression marks a distinct type of mammary stem cells, at two different stages, puberty and early mid-pregnancy. To determine whether s-SHIP is a marker of mammary cancer stem cells (CSCs), we generated bitransgenic mice by crossing the C3(1)-SV40 T-antigen transgenic mouse model of breast cancer, and a transgenic mouse (11.5kb-GFP) expressing green fluorescent protein from the s-SHIP promoter. Here we show that in mammary tumors originating in these bitransgenic mice, s-SHIP promoter expression enriches a rare cell population with CSC activity as demonstrated by sphere-forming assays in vitro and limiting dilution transplantation in vivo. These s-SHIP-positive CSCs are characterized by lower expression of Delta-like non-canonical Notch ligand 1 (DLK1), a negative regulator of the Notch pathway. Inactivation of Dlk1 in s-SHIP-negative tumor cells increases their tumorigenic potential, suggesting a role for DLK1 in mammary cancer stemness.

Identifiants

pubmed: 31204299
pii: S2213-6711(19)30180-8
doi: 10.1016/j.stemcr.2019.05.013
pmc: PMC6626869
pii:
doi:

Substances chimiques

Calcium-Binding Proteins 0
Dlk1 protein, mouse 0
Inpp5d protein, mouse EC 3.1.3.86
Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases EC 3.1.3.86

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10-20

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Cell Stem Cell. 2015 Sep 3;17(3):260-71
pubmed: 26340526
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Oncogene. 2018 Sep;37(39):5305-5324
pubmed: 29858602
J Cell Sci. 2003 May 1;116(Pt 9):1775-86
pubmed: 12665558
Stem Cell Reports. 2018 Jun 5;10(6):1676-1686
pubmed: 29874626
Nat Cell Biol. 2013 Apr;15(4):338-44
pubmed: 23548926
Nature. 2006 Feb 23;439(7079):993-7
pubmed: 16395311
Stem Cells Dev. 2015 May 15;24(10):1252-62
pubmed: 25567531
PLoS One. 2016 May 12;11(5):e0155262
pubmed: 27171183
Stem Cells. 2014 Aug;32(8):2048-60
pubmed: 24802135
Cancer Res. 2008 Oct 1;68(19):7711-7
pubmed: 18829523
Cancer Res. 2008 May 1;68(9):3243-50
pubmed: 18451150
Nat Cell Biol. 2014 Jun;16(6):529-37
pubmed: 24859006
Semin Cancer Biol. 2017 Jun;44:10-24
pubmed: 28257956
J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):51-62
pubmed: 26286174
J Mammary Gland Biol Neoplasia. 2013 Jun;18(2):149-54
pubmed: 23649700
Genome Biol. 2007;8(5):R76
pubmed: 17493263
Adv Cancer Res. 2014;121:331-382
pubmed: 24889535
Cancer Res. 2008 Jun 15;68(12):4674-82
pubmed: 18559513
Blood. 2001 Oct 1;98(7):2028-38
pubmed: 11567986
J Biochem. 2010 Jul;148(1):85-92
pubmed: 20356822
J Cell Biol. 2015 Feb 2;208(3):351-66
pubmed: 25624393
Breast Cancer Res. 2012 Oct 22;14(5):R134
pubmed: 23088371
Stem Cells. 2008 Feb;26(2):364-71
pubmed: 17975224
Genes Dev. 2010 Sep 1;24(17):1882-92
pubmed: 20810647
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Dev Biol. 2005 Jul 15;283(2):503-21
pubmed: 15978570
Science. 2018 Jun 29;360(6396):
pubmed: 29773667
Breast Cancer Res. 2006;8(1):R7
pubmed: 16417656
Curr Protoc Pharmacol. 2016 Mar 18;72:14.38.1-14.38.11
pubmed: 26995547
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
Oncotarget. 2016 May 17;7(20):29228-44
pubmed: 27081082
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40
pubmed: 7972041
Annu Rev Pathol. 2016 May 23;11:47-76
pubmed: 27193450
Endocr Relat Cancer. 2015 Dec;22(6):T161-76
pubmed: 26206777
FASEB J. 2017 Aug;31(8):3484-3496
pubmed: 28461338
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83
pubmed: 21633010
Cancer Res. 2010 Nov 15;70(22):8973-6
pubmed: 21045140
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Genome Biol. 2013 Nov 12;14(11):R125
pubmed: 24220145
Nature. 2006 Jan 5;439(7072):84-8
pubmed: 16397499
Trends Cancer. 2017 Jun;3(6):407-422
pubmed: 28718416

Auteurs

Lu Tian (L)

Université de Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T - Mechanisms of Tumorigenesis and Targeted Therapies, Institut de Biologie de Lille, 1 rue du Professeur Calmette, CS 54447, Lille Cedex 59000/59021, France.

Marie-José Truong (MJ)

Université de Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T - Mechanisms of Tumorigenesis and Targeted Therapies, Institut de Biologie de Lille, 1 rue du Professeur Calmette, CS 54447, Lille Cedex 59000/59021, France.

Chann Lagadec (C)

Université de Lille, INSERM U908 - CPAC - Cell Plasticity and Cancer, Lille 59000, France.

Eric Adriaenssens (E)

Université de Lille, INSERM U908 - CPAC - Cell Plasticity and Cancer, Lille 59000, France.

Emmanuel Bouchaert (E)

Oncovet Clinical Research, SIRIC ONCOLille, Loos 59120, France.

Hélène Bauderlique-Le Roy (H)

BICeL Platform, Institut Pasteur de Lille, Lille 59000, France.

Martin Figeac (M)

Functional Genomics Platform, Université de Lille, Lille 59000, France.

Xuefen Le Bourhis (X)

Université de Lille, INSERM U908 - CPAC - Cell Plasticity and Cancer, Lille 59000, France.

Roland P Bourette (RP)

Université de Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T - Mechanisms of Tumorigenesis and Targeted Therapies, Institut de Biologie de Lille, 1 rue du Professeur Calmette, CS 54447, Lille Cedex 59000/59021, France. Electronic address: roland.bourette@ibl.cnrs.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH